Phase 3 Data on Bimekizumab for Hidradenitis Suppurativa Sho

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

Related Keywords

Berlin , Germany , United States , American , Hidradenitis Suppurativa , European Hidradenitis Suppurativa Foundation , Brandenburg Medical School , American Academy Of Dermatology , European Academy Of Dermatology , Analysis Presented , Bimekizumab Achieved High Thresholds , Clinical Response , American Academy , Dhs , Bimekizumab , Phase 3 ,